ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,116.17
0.32%
US Tech 100
17,281.60
-0.16%
Dow Jones
38,386.09
0.38%
Brent Oil
87.405
0.14%
Bitcoin
61,735.37
-3.29%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Cyclacel Pharmaceuticals Inc (CYCC) Quote

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc (CYCC)

NASDAQ
Add to Watchlist
1.36
-0.15
(-9.93%)
Closed April 29 4:00PM
Delayed by 15 minutes
2.65
1.29
( 94.85% )
Pre Market: 6:14AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.65
Bid
2.64
Ask
2.65
Volume
1,625,429
0.00 Day's Range 0.00
1.30 52 Week Range 13.20
Market Cap
1.146M
Previous Close
1.36
Open
-
Last Trade
6
@
2.65
Last Trade Time
06:14:44
Financial Volume
-
VWAP
-
Average Volume (3m)
128,259
Shares Outstanding
842,855
Dividend Yield
-
PE Ratio
-0.05
Earnings Per Share (EPS)
-27
Revenue
420k
Net Profit
-22.76M

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitor... Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.cyclacel.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Cyclacel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CYCC. The last closing price for Cyclacel Pharmaceuticals was $1.36. Over the last year, Cyclacel Pharmaceuticals shares have traded in a share price range of $ 1.30 to $ 13.20.

Cyclacel Pharmaceuticals currently has 842,855 shares outstanding. The market capitalization of Cyclacel Pharmaceuticals is $1.15 million. Cyclacel Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.05.

CYCC Latest News

More News

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J...

April 01 2024
GlobeNewswire Inc.

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...

March 19 2024
GlobeNewswire Inc.

US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat

In Tuesday’s pre-market trading, U.S. index futures are pointing to a decline, reflecting investors’ caution as they analyze revelations from Nvidia’s artificial intelligence...

March 19 2024
IH Market News

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

March 13 2024
GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

March 07 2024
GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

March 06 2024
GlobeNewswire Inc.

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

February 20 2024
GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

January 30 2024
GlobeNewswire Inc.

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage...

December 18 2023
GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Reverse Stock Split

BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

December 12 2023
GlobeNewswire Inc.

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CYCCCyclacel Pharmaceuticals Inc
$ 2.66
(95.59%)
1.58M
WGSGeneDx Holdings Corporation
$ 14.69
(33.55%)
87.33k
MRINMarin Software Incorporated
$ 3.32
(27.20%)
295.66k
GWAVGreenwave Technology Solutions Inc
$ 0.0806
(24.00%)
19.76M
STSSSharps Technology Inc
$ 0.318
(23.59%)
100
LICNLichen China Limited
$ 1.52
(-25.12%)
171.33k
EGOXNext e GO NV
$ 0.0233
(-15.58%)
1.19M
ICLKiClick Interactive Asia Group Ltd
$ 1.00
(-15.25%)
330
CSLRComplete Solaria Inc
$ 0.6305
(-13.65%)
78.21k
BSGMBioSig Technologies Inc
$ 1.16
(-13.43%)
2.18k
GWAVGreenwave Technology Solutions Inc
$ 0.0806
(24.00%)
19.76M
JAGXJaguar Health Inc
$ 0.2339
(12.45%)
3.19M
FFIEFaraday Future Intelligent Electric Inc
$ 0.0442
(5.74%)
2.13M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 8.89
(-5.02%)
1.6M
CYCCCyclacel Pharmaceuticals Inc
$ 2.66
(95.59%)
1.58M

CYCC Discussion

View Posts
TheFinalCD TheFinalCD 9 hours ago
https://twitter.com/Cbmcgee2/status/1783238416601137262/photo/1
👍️0
tw0122 tw0122 13 hours ago
No offering…The Company has determined not to pursue, at this time, the public offering to which the Registration Statement relates. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.

The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company respectfully requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement or registration statements.
👍️0
Monksdream Monksdream 13 hours ago
What happened? I spent the afternoon posting new highs and lows
👍️0
Awl416 Awl416 13 hours ago
What leaked
👍️0
Monksdream Monksdream 17 hours ago
CYCC under $2
👍️0
Awl416 Awl416 5 days ago
What I miss?
👍️0
Monksdream Monksdream 1 month ago
CYCC 10Q due 3/19
👍️0
chsmoke chsmoke 3 months ago
while s. robotis has certainly got to be in the running for longest serving, worst performing CEO of any American company
in history, one has to admire that decade after decade he is able to draw a sizeable paycheck, while keeping his
handpicked and doubtlessly corrupt bod in his back pocket. he could teach a valuable course at any business school.
what a great subject for a great novel cycc and it's unapologetic, feckless leader would make.
go Spiro go--and you know he will do just that!
👍️0
Monksdream Monksdream 4 months ago
CYCC new 52 week low
👍️0
chsmoke chsmoke 6 months ago
how has Spiro kept his job?
is there a functioning board of directors?
he's been drawing a big salary without a single thing for an investor to feel good about for so many years. ??????
👍️0
glenn1919 glenn1919 7 months ago
CYCC.......................................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 8 months ago
CYCC new 52. Week low
👍️0
Monksdream Monksdream 8 months ago
CYCC new 52 week low
👍️0
Monksdream Monksdream 8 months ago
CYCC new 52 week low
👍️0
glenn1919 glenn1919 9 months ago
CYCC............................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783
👍️0
Triple nickle Triple nickle 9 months ago
Nice buy
👍️0
Cytobeliever Cytobeliever 1 year ago
Sar Pas,

No reply to my last post! The stock is now at 73 cents. Get out while you can. It is not on fire! I can't beleive that you have not responded.

He is a scammer and it will soon be delisted or he will have to do another offering. I lost thousands years ago. It is what Spiro does. He keeps on sucking in new money so that he can live the life of luxury while we all lose our shirts. That is what he does. Everyone needs to run as fast as possible and take their loses. This guy and his board should be shut down. I can't stand to see what you are all going through! Get out Now!
👍️0
Cytobeliever Cytobeliever 1 year ago
So what do you have to say now? Spiro has been sucking in people for years. Prepare yourself for another reverse split so that he can keep the money rolling in. I lost thousands years ago. He is a scammer! Run!
👍️0
judgeybrown judgeybrown 2 years ago
Ihub is a valueless waste land
👍️0
SarPas SarPas 2 years ago
Stock is on fire in PM and nobody to comment ? Closed at $1.31 and was up to $1.99 in PM. Wake up people.
👍️0
judgeybrown judgeybrown 2 years ago
That was nice :) moving on.
👍️0
judgeybrown judgeybrown 2 years ago
This should be the week. See what the universe delivers on this opp. It does what it wants.
👍️0
chsmoke chsmoke 2 years ago
spiro rombotis. not just in the usa, but globally, he would be right at the
very top of highest paid, longest standing, and worst ceos. can't even imagine
how corrupt the board is. if he has family, not even they would've let him
keep his job. he's smart, he's very articulate, hard to imagine a bigger fraudster.
if cycc wasn't what it is, he would've been out 10 years ago. or more...
👍️0
judgeybrown judgeybrown 2 years ago
Nobody needs to be in here now. But ya’ll will be checking in here later cause we gonna blow this up
👍️0
Awl416 Awl416 2 years ago
Movement PM
👍️0
alvaroc2 alvaroc2 2 years ago
Enter ar 3,80, bullish by TA, regards
👍️0
trickledownfacists trickledownfacists 3 years ago
AH boom
👍️0
chsmoke chsmoke 3 years ago
just the fact that spiro and his cohort, i mean cfo, have had
their ludicrous contracts extended is enough to drop the value
of the company almost by 1/5th. the bod of cycc, they must be
some bunch. spiro, he's almost too bad to be true. smart? he is that. deserving to keep his job? oh lord love a duck. even if he
paid himself nothing instead of the ludicrous salary he is paid
he should've been ousted many years ago...
👍️0
swingingRichard swingingRichard 3 years ago
We find stuff like CYCC and, unlike the the "mud merchant" we tell you about them BEFORE they pop. This way, you've got a chance to make money and not just be sitting there after the explosion watching a video of some guy drawing arbitrary lines and pontificating about the stock might go up or it might go down.

This chart was looking fantastic June of last year.



👍️0
02opida 02opida 3 years ago
Highs are good
👍️0
Value_Investor Value_Investor 3 years ago
CYCC hit Another New high $4.45 so far! It is heading onto $4.68 now since the Bottom was $3.12...

👍️0
Value_Investor Value_Investor 3 years ago
Another New high $4.34 today! CYCC is heading onto $20 again...

CYCC is much much much cheaper than all its COVID-19 peers now!


👍️0
Eaglepointone Eaglepointone 3 years ago
I hope the price stabilizes, 3 - 4$
👍️0
Value_Investor Value_Investor 3 years ago
CYCC just hit a New high $4.35 in the Pre-Market session of today! We should see $6 again as soon as tomorrow...

To replicate the Same 7.413-Bagger Strong performance with its NASDAQ-peer (HUSA), CYCC will surge to $23.13 which is 5.74 Times of its current ridiculous low price $4.03!

👍️0
02opida 02opida 3 years ago
nice
👍️0
Value_Investor Value_Investor 3 years ago
CYCC hit $4.19 today! We should see $6 again as soon as this week...

Super Undervalued now! Hyper Oversold --- from nearly $20 to $3.12!
👍️0
02opida 02opida 3 years ago
CYCC ~ looks okay
👍️0
Value_Investor Value_Investor 3 years ago
Yes, CYCC bounced to $3.98 today! We should see it soar back to $20 again before the end of 2020 since the company is developing COVID-2019 related hot drugs...

👍️0
Value_Investor Value_Investor 3 years ago
CYCC has Very Good News after the market close --- no more share's dilution to raise the cash till 12/31/2022!

CYCC has $4.76 per share Cash Value and $5.03 per share Book Value now!

So it is Extremely Undervalued currently! At Hyper Oversold status now --- from $19.xx to $3.12!

Thus it will Quickly And Easily surge back to its most recent high $19.xx (i.e. nearly $20) again...

CYCC might replicate 7.143-Bagger Quick rally to hit $22.29 like its NASDAQ-peer (HUSA) did!

👍️0
02opida 02opida 4 years ago
will move up some
👍️0
Value_Investor Value_Investor 4 years ago
Yes, CYCC seems Bottomed out at $3.19! It bounced to $4.25 so far! Easy to surge back to $6.00 again since its most recent high was nearly $20.00...

👍️0
02opida 02opida 4 years ago
north is good
👍️0
Value_Investor Value_Investor 4 years ago
Can CYCC test its most recent high $6.00 in the next week?
👍️0
Value_Investor Value_Investor 4 years ago
CYCC should run in the next week unless any bad news kicks in...
👍️0
Value_Investor Value_Investor 4 years ago
Hyper Oversold --- from $20.xx to $3.23?
👍️0
Value_Investor Value_Investor 4 years ago
CYCC has bounced to $3.87 so far from the New Bottom $3.23!
👍️0
02opida 02opida 4 years ago
will announce second quarter 2020 financial results on Wednesday, August 12, 2020. The Company will host a conference call and live webcast at 4:30 p.m
👍️0
dinogreeves dinogreeves 4 years ago
3-4 catalyst awaiting this year for this thing, I would not doubt we will be trading in the teens soon before the end of the year, especially the news regarding their COVID phase in Scotland.
👍️0
stock1ace1 stock1ace1 4 years ago
Riding the waves !
👍️0
dinogreeves dinogreeves 4 years ago
News very soon.
👍️0

Your Recent History

NASDAQ
CYCC
Cyclacel Pharmaceuticals
CCOM
OILBRENT
Brent Oil
PM
XAUUSD
Gold vs US Dollar
COIN
BTCUSD
Bitcoin
NASDAQI
COMP
NASDAQ Composite
SPI
SP500
S&P 500
NASDAQ
MSFT
Microsoft
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved